Latest News

blank
Clinical Trials

Ivermectin for Prevention and Treatment of COVID-19 Infection

Moderate-certainty evidence finds that large reductions in COVID-19 deaths are possible using ivermectin. Using ivermectin early in the clinical course may reduce numbers progressing to severe disease. The apparent safety and low cost suggest that ivermectin is likely to have a significant impact on the SARS-CoV-2 pandemic globally.

Read More »
blank
Azithromycin

HYDROXYCHLOROQUINE – Observational Study on 255 Mechanically Ventilated Covid Patients at the Beginning of the USA Pandemic

Most Covid studies have not considered days of therapy, cumulative dose, or weight-adjusted dosing. We found that when the cumulative doses of two drugs, HCQ and AZM, were above a certain level, patients had a survival rate 2.9 times the other patients. By using causal analysis and considering of weight-adjusted cumulative dose, we prove the combined therapy, >3 g HCQ and > 1g AZM greatly increases survival in Covid patients on IMV and that HCQ cumulative dose > 80 mg/kg works substantially better. These data do not yet apply to hospitalized patients not on IMV. Since those with higher doses of HCQ had higher doses of AZM, we cannot solely attribute the causal effect to HCQ/AZM combination therapy. However, it is likely AZM does contribute significantly to this increase in survival rate. Since higher dose HCQ/AZM therapy improves survival by nearly 200% in this population, the safety data are moot. However, given the data presented here, the studies reporting HCQ’s effect of QTc intervals need to be re-evaluated.

Read More »
blank
Ivermectin

The International Ivermectin for Covid Conference​: Medical ethics and ivermectin

As Head of the Department of Medical Ethics and Law, Medical Faculty, University of Maribor, Slovenia, Prof. Matjaž Zwitter presents current ethical issues around ivermectin for covid-19. His two papers on ivermectin for Covid-19, as published in Slovenian medical journal Isis and in leading newspaper Delo stirred a vivid debate among medical and lay community, hopefully leading to a change in current medical practice.

Read More »
blank
Africa

How much proof do you want? Hundreds of studies conclude – treat Covid-19 early with hydroxychloroquine!

HCQ is effective for COVID-19. The probability that an ineffective treatment generated results as positive as the 235 studies to date is estimated to be 1 in 6 quadrillion (p = 0.00000000000000018).
Early treatment is most successful, with 100% of 29 studies reporting a positive effect (13 statistically significant in isolation) and an estimated reduction of 65% in the effect measured (death, hospitalization, etc.) using a random effects meta-analysis, RR 0.35 [0.25-0.50].
92% of Randomized Controlled Trials (RCTs) for early, PrEP, or PEP treatment report positive effects, the probability of this happening for an ineffective treatment is 0.0017.

Read More »
blank
China

Hyperglycemia, hydroxychloroquine and the COVID‐19 pandemic

Hydroxychloroquine also can act as an oral hypoglycemic agent, as patients with diabetes taking hydroxychloroquine for rheumatologic diseases had a significant reduction in hemoglobin A1c when compared to methotrexate,40 and thus can serve to reduce hyperglycemia, a possible COVID‐19 risk factor for disease severity.

Read More »
blank
Hydroxychloroquine

Clinical outcomes of patients with mild COVID-19 following treatment with hydroxychloroquine in an outpatient setting

Our investigation of a large national cohort appears to support early administration (within the first 3 to 7 days of COVID-19 diagnosis) of HCQ in mild COVID-19 disease in an outpatient setting for reducing hospitalizations and deaths without any serious adverse HCQ-related effects.
If this finding is confirmed in future clinical trials, HCQ as a cheap and available drug may still play a role in a specific population with respect to reducing COVID-19 burden, particularly in resource-poor countries.

Read More »
blank
Argentina

A RANDOMIZED TRIAL – INTENSIVE TREATMENT BASED IN IVERMECTIN AND IOTA-CARRAGEENAN AS PRE-EXPOSURE PROPHYLAXIS FOR COVID- 19 IN HEALTHCARE AGENTS

The purpose of this study was to assess the effect of oral Ivermectin treatment, which has been associated with iota-carrageenan in repeated doses through the nasal and oral topical route, on the appearance and eventual progression of COVID-19 disease in a healthy population that are exposed to it and have a higher risk of contagion of SARS-COV-2 for being health personnel from

Read More »
blank
Hydroxychloroquine

Structural basis of anti-SARS-CoV-2 activity of hydroxychloroquine: specific binding to NTD/CTD and disruption of LLPS of N protein

In this study, by use of DIC microscopy and NMR spectroscopy, for the first time we have decoded that HCQ specifically binds to both N-terminal domain (NTD) and C-terminal domain (CTD) of SARS-CoV-2 nucleocapsid (N) protein to inhibit their interactions with nucleic acids (NAs), as well as to disrupt its NA-induced liquid-liquid phase separation (LLPS) essential for the viral life cycle including the package of gRNA and N protein into new virions.

Read More »
blank
India

Role of ivermectin in the prevention of SARS-CoV-2 infection among healthcare workers in India: A matched case-control study

We conclude that two-dose ivermectin prophylaxis at a dose of 300 μg/kg body weight with a gap of 72 hours was associated with a 73% reduction of SARS-CoV-2 infection among HCWs in the following one month. Chemoprophylaxis has relevance in the containment of pandemic. This is an intervention worth replicating at other centers until a vaccine is widely available.

Read More »
blank
Hydroxychloroquine

HCQ Peer-reviewed: Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection

American Journal of Medicine announces peer-reviewed early outpatient treatment protocol for Covid19 including hydroxychloroquine. Acute COVID-19 has a great range of clinical severity from asymptomatic to fatal. In the absence of clinical trials and guidelines, with hospitalizations and mortality mounting, it is prudent to deploy treatment for COVID-19 based on pathophysiological principles.

Read More »
blank
Azithromycin

Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study

Source: Science Direct PhilippeGautretab1Jean-ChristopheLagierac1PhilippeParolaabVan ThuanHoangabdLineMeddebaJacquesSevestreaMorganeMailheaBarbaraDoudieraCamilleAubryaSophieAmraneaPisethSengaMarieHocquartaCaroleEldinabJulieFinanceeVera EstevesVieiraaHervé TissotTissot-DupontacStéphaneHonoréfgAndreasSteinacMatthieuMillionacPhilippeColsonacBernardLa ScolaacVéroniqueVeithAlexisJacquieriJean-ClaudeDeharojMichelDrancourtacPierre EdouardFournierabJean-MarcRolainacPhilippeBrouquiacDidierRaoultac aIHU-Méditerranée Infection, Marseille, France bAix Marseille

Read More »
blank
A Doctor's Story

NY Doctor Proved Everyone Wrong About Hydroxychloroquine

According to Zelenko, “HCQ is the safest medication in the history of medicine, azithromycin is one of the most common antibiotics used in medicine, and zinc is a mineral that’s well-known and well-tolerated. These drugs were affordable and available to take at home, which was very important. And they worked.”

Read More »
blank
A Doctor's Story

Trouble in Paradise Surrounding the use of Ivermectin

In nations around the world tension mounts between physicians and caregivers seeking to prescribe what they professionally deem as safe doses of ivermectin, as an off-label treatment for COVID-19 and national health authorities, which for the most part have all taken a hostile and oppositional position against the use of the drug.

Read More »
blank
Ivermectin

How Ivermectin became a Target for the ‘Fraud Detectives.’

And why is ivermectin being so negatively targeted by Big Tech and Big Media? One could argue conflict of interest plays a major role, given how intertwined they are with Big Pharma and the far-reaching grasp of the BMGF. A cheap and effective early treatment for Covid-19, like ivermectin, can be seen as a significant threat to the financial interests of those involved with Covid vaccines and expensive anti-viral drugs.

Read More »
blank
A Doctor's Story

Canada: Alberta Failing on COVID-19 Vaccines and Treatment

Numerous studies and clinical observation of thousands of patients has indicated that Ivermectin is highly effective in this regard. Even low dose studies that were designed to reach the conclusion that ivermectin was not effective found a signal that indicated that Ivermectin effectively interacted with the COVID virus molecule to prevent or lessen replication of the virus.”

Read More »

About The Foundation

Clive-Palmer_res (9)

The Palmer Foundation is the philanthropic entity owned by the Palmer family, headed by Clive Palmer. 

The Palmer Foundation is a private entity that engages in charitable projects that enable better welfare of others, and society as a whole. 

The foundations most recent endeavour revolves around the response to, and action on the COVID-19 Virus pandemic for the treatment of all Australians in need.

Click here to get the background on The Palmer Foundations COVID-19 Response.

 

Share on facebook
Share on twitter
Share on whatsapp
On Trend

Popular Stories

blank
A Doctor's Story

NY Doctor Proved Everyone Wrong About Hydroxychloroquine

According to Zelenko, “HCQ is the safest medication in the history of medicine, azithromycin is one of the most common antibiotics used in medicine, and zinc is a mineral that’s well-known and well-tolerated. These drugs were affordable and available to take at home, which was very important. And they worked.”

Read More »